Orion Pharma reports Phase I data from TEADES trial for solid tumours

Orion Pharma has reported data from the Phase I segment of its ongoing Phase I/II TEADES trial, assessing ODM-212 in patients with advanced solid tumours. The results showed ODM-212 was well tolerated, with no dose-limiting toxicities and no maximum tolerated dose reached. The most common TRAE was reversible proteinuria, seen in 19.7% of patients and requiring 7.9% treatment adjustments. Credit: Gorodenkoff / Shutterstock.com. Orion Pharma has reported data from the Phase I segment of its ongoing Phase I/II TEADES trial, assessing ODM-212 in patients with advanced solid tumours. The open-label, first-in-human, multi-site trial evaluated the tolerability, safety, and preliminary efficacy…

Source: Clinical Trials Arena